Biocon Gets USFDA Observations for Bengaluru API Facility

Sep 28, 2024 17:49

Biocon's Bengaluru-based API facility received four observations from the USFDA following an inspection. The company plans to address the observations within the stipulated time.

Photograph: Kind courtesy Biocon

New Delhi, Sep 28 (PTI) Biocon on Saturday said the US health regulator has issued four observations after inspecting its Bengaluru-based API (active pharmaceutical ingredient) facility.

The US Food and Drug Administration (USFDA) conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024, the company said in a regulatory filing.

"Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time," it added.

The company does not foresee any impact on the business, Biocon said.

Source: PTI

MORE NEWS

AI Powers MIF Manufacturing with Humanoid Robots

Mother India Forming (MIF) transforms manufacturing with AI-powered humanoid &...

SBI MD: Concerns Over Account Aggregator Consent

SBI MD Ashwini Kumar Tewari raises concerns about Account Aggregator's single consent...

Silver Hits Record High on Fed Rate Cut Hopes

Silver futures soar to Rs 1.91 lakh/kg on Fed rate cut expectations. Gold rises. Market...

SpiceJet Adds 100 Daily Flights for Winter Demand

SpiceJet plans to add up to 100 daily flights this winter to meet growing demand and...

2 Lakh Startups Recognised by Govt: Startup India

Government recognizes over 2 lakh startups under Startup India. Incentives, job...

Waaree Energies: 1 GW Solar Module Output Record

Waaree Energies achieves record 1 GW monthly solar module output in November 2025, a...

India FTA Talks with Oman, New Zealand Nearing End

Piyush Goyal announces FTA negotiations with Oman, New Zealand in final stages. Trade...

Telangana to Launch Rs 1,000 Cr Startup Fund

Telangana CM announces Rs 1,000 crore startup fund to boost Hyderabad as a unicorn hub....

ADB Raises India GDP Growth Forecast to 7.2%...

ADB sharply revises India''s GDP growth forecast upward to 7.2% for FY26, driven by...

India, EU FTA Talks Progress: Goyal Comments

Piyush Goyal says India and EU are committed to early conclusion of FTA negotiations. A...

Biocon Gets USFDA Observations for Bengaluru API Facility

You May Like To Read

MORE NEWS